Bioceltix (BCX) Q4 2025 earnings summary

Executive summary

• Achieved major clinical, regulatory, and organizational milestones in 2025, advancing three key cell therapy products for veterinary use toward commercialization.

• Submitted BCX-EM (for equine arthritis) for EMA approval; BCX-CM-AD (for canine atopic dermatitis) met primary clinical endpoints; BCX-CM-J (for canine osteoarthritis) advanced in registration, with dossier response postponed to May 2026.

• Secured GMP certification, strengthening readiness for commercial production and regulatory processes.

• Raised PLN 53 million gross via share issues to fund new manufacturing facility and operations.

• Maintained strong financial position, enabling continued R&D and investment activities.

Financial highlights

• No product sales revenue in 2025; net loss of PLN 15.16 million, similar to prior year.

• Operating loss: PLN 15.24 million; net cash outflow from operations: PLN 11.95 million.

• Net cash from financing: PLN 48.69 million; year-end cash: PLN 68.40 million (up from PLN 33.63 million in 2024).

• Equity: PLN 73.28 million; total assets: PLN 75.63 million; low debt ratio (3.1%).

• Book value per share: PLN 13.25 (up from PLN 7.80 in 2024).

Outlook and guidance

• Focused on reducing regulatory risks, advancing product portfolio, and preparing for commercial launch post-EMA approvals.

• Construction of new manufacturing facility underway, with production start targeted for 2027.

• Exploring US market entry with regulatory advisory partnership initiated in April 2026.

• Sufficient cash for at least 12 months of operations; further funding may be sought as needed.